Skip to main content
. 2022 Dec 28;28(4):333–340. doi: 10.1093/oncolo/oyac243

Figure 1.

Figure 1.

Durations of confirmed objective responses. Includes responses in patients on study; responses after switching to commercial avelumab plus axitinib were censored.